ALS Drug Development Gets FDA Hearing, Could See Push For Surrogate Markers
This article was originally published in The Pink Sheet Daily
Executive Summary
The ALS Association says it worked with FDA to seek a public forum in which ALS patients can present their perspective on benefit/risk in development of drugs for their condition.
You may also be interested in...
Patient Community Is FDA’s “Guiding Light” On Acceptable Drug Risks
CDER’s Janet Woodcock says the community has the agency’s ear when it advocates new developments; cites need for an “adult conversation” in assessing when drugs should be made available to patients.
Disease-Of-The-Quarter Club: FDA Plans 20 Patient Network Meetings Over Five Years
PDUFA V framework to involve patients in the creation of the risk-benefit criteria for various diseases kicks off before the legislation is even enacted.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.